Description

Simple

A medication used to treat seasonal allergies and allergic skin reactions.

Clinical

A second generation tricyclic antihistamine used to treat seasonal and non seasonal allergic rhinitis, pruritus, and urticaria.

Overview

Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.

Pharmacology

Indication

For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.

Pharmacodynamic

Desloratadine is a long-acting second-generation H1-receptor antagonist which has a selective and peripheral H1-antagonist action. Histamine is a chemical that causes many of the signs that are part of allergic reactions, such as the swelling of tissues. Histamine is released from histami... Read more

Mechanism of action

Like other H1-blockers, Desloratadine competes with free histamine for binding at H1-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (... Read more

Absorption

Information currently not available.

Protein binding

82-87%

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

50 hours

Route of elimination

Desloratadine (a major metabolite of loratadine) is extensively metabolized to 3-hydroxydesloratadine, an active metabolite, which is subsequently glucuronidated. Approximately 87% of a 14C-desloratadine dose was equally recovered in urine and feces.

Toxicity

Information currently not available.

Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Upper Respiratory Tract Infection US
  • pediatric
  • Kind: experimental
    • Percent: 21.2%
  • Kind: placebo
    • Percent: 12.9%
  • Clinical Trial
    Diarrhea US
    • pediatric
  • Kind: experimental
    • Percent: 19.7%
  • Kind: placebo
    • Percent: 8.1%
  • Clinical Trial
    Fever US
    • pediatric
  • Kind: experimental
    • Percent: 16.9%
  • Kind: placebo
    • Percent: 12.9%
  • Clinical Trial
    Diarrhea US
    • pediatric
  • Kind: experimental
    • Percent: 15.4%
  • Kind: placebo
    • Percent: 11.3%
  • Clinical Trial
    Headache US
    • adolescent
    • adult
  • Kind: experimental
    • Percent: 14%
  • Kind: placebo
    • Percent: 13%
  • Clinical Trial
    Fever US
    • pediatric
  • Kind: experimental
    • Percent: 12.1%
  • Kind: placebo
    • Percent: 1.6%
  • Clinical Trial
    Irritability US
    • pediatric
  • Kind: experimental
    • Percent: 12.1%
  • Kind: placebo
    • Percent: 11.3%
  • Clinical Trial
    Respiratory Tract Infections US
    • pediatric
  • Kind: experimental
    • Percent: 10.8%
  • Kind: placebo
    • Percent: 9.7%
  • Clinical Trial
    Coughing US
    • pediatric
  • Kind: experimental
    • Percent: 10.8%
  • Kind: placebo
    • Percent: 6.5%
  • Clinical Trial
    Coughing US
    • pediatric
  • Kind: experimental
    • Percent: 10.6%
  • Kind: placebo
    • Percent: 9.7%
  • Clinical Trial
    Somnolence US
    • pediatric
  • Kind: experimental
    • Percent: 9.1%
  • Kind: placebo
    • Percent: 8.1%
  • Clinical Trial
    Bronchitis US
    • pediatric
  • Kind: experimental
    • Percent: 6.1%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Otitis Media US
    • pediatric
  • Kind: experimental
    • Percent: 6.1%
  • Kind: placebo
    • Percent: 1.6%
  • Clinical Trial
    Vomiting US
    • pediatric
  • Kind: experimental
    • Percent: 6.1%
  • Kind: placebo
    • Percent: 3.2%
  • Clinical Trial
    Fever US
    • pediatric
  • Kind: experimental
    • Percent: 5.5%
  • Kind: placebo
    • Percent: 5.4%
  • Clinical Trial
    Nausea US
    • adolescent
    • adult
  • Kind: experimental
    • Percent: 5%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Fatigue US
    • adolescent
    • adult
  • Kind: experimental
    • Percent: 5%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Rhinorrhea US
    • pediatric
  • Kind: experimental
    • Percent: 4.5%
  • Kind: placebo
    • Percent: 3.2%
  • Clinical Trial
    Insomnia US
    • pediatric
  • Kind: experimental
    • Percent: 4.5%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Pharyngitis US
    • pediatric
  • Kind: experimental
    • Percent: 4.5%
  • Kind: placebo
    • Percent: 1.6%
  • Clinical Trial
    Anorexia US
    • pediatric
  • Kind: experimental
    • Percent: 4.5%
  • Kind: placebo
    • Percent: 1.6%
  • Clinical Trial
    Pharyngitis US
    • adolescent
    • adult
  • Kind: experimental
    • Percent: 4.1%
  • Kind: placebo
    • Percent: 2.0%
  • Clinical Trial
    Dizziness US
    • adolescent
    • adult
  • Kind: experimental
    • Percent: 4%
  • Kind: placebo
    • Percent: 3%
  • Clinical Trial
    Urinary Tract Infection US
    • pediatric
  • Kind: experimental
    • Percent: 3.6%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Varicella US
    • pediatric
  • Kind: experimental
    • Percent: 3.6%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Increased appetite US
    • pediatric
  • Kind: experimental
    • Percent: 3.1%
  • Kind: placebo
    • Percent: 1.6%
  • Clinical Trial
    Emotional Lability US
    • pediatric
  • Kind: experimental
    • Percent: 3.1%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Epistaxis US
    • pediatric
  • Kind: experimental
    • Percent: 3.1%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Parasitic infection US
    • pediatric
  • Kind: experimental
    • Percent: 3.1%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Pharyngitis US
    • pediatric
  • Kind: experimental
    • Percent: 3.1%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Maculopapular rash US
    • pediatric
  • Kind: experimental
    • Percent: 3.1%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Myalgia US
    • adolescent
    • adult
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Dyspepsia US
    • adolescent
    • adult
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Pharyngitis US
    • adolescent
    • adult
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Nausea US
    • pediatric
  • Kind: experimental
    • Percent: 3.0%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Erythema US
    • pediatric
  • Kind: experimental
    • Percent: 3.0%
  • Kind: placebo
    • Percent: 1.6%
  • Clinical Trial
    Dry Mouth US
    • adolescent
    • adult
  • Kind: experimental
    • Percent: 3.0%
  • Kind: placebo
    • Percent: 1.9%
  • Clinical Trial
    Dysmenorrhea US
    • adolescent
    • adult
  • Kind: experimental
    • Percent: 2.1%
  • Kind: placebo
    • Percent: 1.6%
  • Clinical Trial
    Somnolence US
    • adolescent
    • adult
  • Kind: experimental
    • Percent: 2.1%
  • Kind: placebo
    • Percent: 1.8%
  • Clinical Trial
    Myalgia US
    • adolescent
    • adult
  • Kind: experimental
    • Percent: 2.1%
  • Kind: placebo
    • Percent: 1.8%
  • Clinical Trial
    Fatigue US
    • adolescent
    • adult
  • Kind: experimental
    • Percent: 2.1%
  • Kind: placebo
    • Percent: 1.2%
  • Clinical Trial
    Hepatitis US
    Post Marketing
    Elevated Liver Enzymes US
    Post Marketing
    Seizures US
    Post Marketing
    Hypersensitivity reactions US
    Post Marketing
    Psychomotor hyperactivity US
    Post Marketing
    Tachycardia US
    Post Marketing
    Palpitations US
    Post Marketing

    Contraindications

    • Route:
      • Oral
    • Hypersensitivity:
      • loratidine
    • Regions: US

    Food Interactions

    Take with or without food. The absorption is unaffected by food.